Mesa Laboratories (MLAB) 10-Q 6 Nov 23 2024 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Sep. 30, 2023	Oct. 30, 2023
Document Information [Line Items]
Entity Central Index Key	0000724004
Entity Registrant Name	MESA LABORATORIES INC /CO
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2024
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity File Number	0-11740
Entity Incorporation, State or Country Code	CO
Entity Tax Identification Number	84-0872291
Entity Address, Address Line One	12100 West Sixth Avenue
Entity Address, City or Town	Lakewood
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80228
City Area Code	303
Local Phone Number	987-8000
Title of 12(b) Security	Common Stock, no par value
Trading Symbol	MLAB
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		5,391,726

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2023	Mar. 31, 2023
Cash and cash equivalents	$ 35,617	$ 32,910
Accounts receivable, less allowance for doubtful accounts of $979 and $849, respectively	36,340	42,551
Inventories	32,879	34,642
Prepaid expenses and other	12,826	8,872
Total current assets	117,662	118,975
Noncurrent assets:
Property, plant and equipment, net of accumulated depreciation of $21,324 and $19,768 respectively	28,574	28,149
Deferred tax asset	1,051	1,076
Other assets	8,953	10,373
Intangible assets	197,680	216,815
Goodwill	283,268	286,444
Total assets	637,188	661,832
LIABILITIES AND STOCKHOLDERS’ EQUITY
Accounts payable	4,810	6,134
Accrued payroll and benefits	8,353	9,433
Unearned revenues	14,316	15,694
Other accrued expenses	12,337	12,098
Total current liabilities	39,816	43,359
Noncurrent liabilities:
Deferred tax liability	33,437	34,028
Other long-term liabilities	5,443	7,693
Credit Facility	0	13,000
Convertible senior notes, net of debt issuance costs	170,733	170,272
Total liabilities	249,429	268,352
Stockholders’ equity:
Common stock, no par value; 25,000,000 shares authorized; 5,391,726 and 5,369,466 shares issued and outstanding, respectively	337,869	332,076
Retained earnings	70,699	74,199
Accumulated other comprehensive (loss)	(20,809)	(12,795)
Total stockholders’ equity	387,759	393,480
Total liabilities and stockholders’ equity	637,188	661,832
Customer Relationships [Member]
Noncurrent assets:
Intangible assets	137,057	152,189
Intellectual Property [Member]
Noncurrent assets:
Intangible assets	43,416	46,400
Other Intangible Assets [Member]
Noncurrent assets:
Intangible assets	$ 17,207	$ 18,226

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ / shares in Thousands, $ in Thousands	Sep. 30, 2023	Mar. 31, 2023
Allowance for doubtful accounts receivable	$ 979	$ 849
Property, plant and equipment, accumulated Depreciation	$ 21,324	$ 19,768
Common stock, no par value (in dollars per share)	$ 0	$ 0
Common stock, authorized (in shares)	25,000,000	25,000,000
Common stock, issued (in shares)	5,391,726	5,369,466
Common stock, outstanding (in shares)	5,391,726	5,369,466

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenues	$ 53,165	$ 58,749	$ 103,810	$ 109,202
Cost of revenues	21,056	22,363	40,518	41,475
Gross profit	32,109	36,386	63,292	67,727
Operating expense:
Selling	9,650	9,200	18,626	19,223
General and administrative	17,526	18,202	35,586	38,414
Research and development	4,993	4,989	9,804	10,689
Total operating expense	32,169	32,391	64,016	68,326
Operating (loss) income	(60)	3,995	(724)	(599)
Nonoperating expense:
Interest expense and amortization of debt issuance costs	905	1,214	1,953	2,228
Other expense (income), net	360	(603)	(415)	(799)
Total nonoperating expense, net	1,265	611	1,538	1,429
(Loss) earnings before income taxes	(1,325)	3,384	(2,262)	(2,028)
Income tax (benefit) expense	(95)	2,078	(483)	(1,896)
Net (loss) income	$ (1,230)	$ 1,306	$ (1,779)	$ (132)
Net (loss) earnings per share:
Basic (loss) earnings per share (in dollars per share)	$ (0.23)	$ 0.25	$ (0.33)	$ (0.02)
Diluted (loss) earnings per share (in dollars per share)	$ (0.23)	$ 0.24	$ (0.33)	$ (0.02)
Weighted-average common shares outstanding:
Basic (in shares)	5,387	5,323	5,379	5,298
Fully diluted shares (in shares)	5,387	5,364	5,379	5,298

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive (Loss) (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Net (loss)	$ (1,230)	$ 1,306	$ (1,779)	$ (132)
Other comprehensive (loss):
Foreign currency translation	(1,353)	(13,226)	(8,014)	(29,183)
Comprehensive (loss)	$ (2,583)	$ (11,920)	$ (9,793)	$ (29,315)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]		Total
Balance (in shares) at Mar. 31, 2022	5,265,627
Balance at Mar. 31, 2022	$ 313,460	$ 76,675	$ 3,666	[1]	$ 393,801
Exercise of stock options and vesting of restricted stock units (in shares)	31,690
Exercise of stock options and vesting of restricted stock units	$ 1,438				1,438
Tax withholding on vesting of restricted stock units (in shares)	(9)
Tax withholding on vesting of restricted stock units	$ (2)	0	0		(2)
Dividends paid, $0.16 per share		(843)			(843)
Stock-based compensation expense	3,432				3,432
Foreign currency translation			(15,957)	[1]	(15,957)
Net (loss) income	$ 0	(1,438)			(1,438)
Balance (in shares) at Jun. 30, 2022	5,297,308
Balance at Jun. 30, 2022	$ 318,328	74,394	(12,291)	[1]	380,431
Exercise of stock options and vesting of restricted stock units (in shares)	42,014
Exercise of stock options and vesting of restricted stock units	$ 2,778				2,778
Tax withholding on vesting of restricted stock units (in shares)	(3,051)
Tax withholding on vesting of restricted stock units	$ (572)				(572)
Dividends paid, $0.16 per share		(852)			(852)
Stock-based compensation expense	$ 4,371				4,371
Foreign currency translation			(13,226)		(13,226)
Net (loss) income		1,306			1,306
Balance (in shares) at Sep. 30, 2022	5,336,271
Balance at Sep. 30, 2022	$ 324,905	74,848	(25,517)	[1]	$ 374,236
Balance (in shares) at Mar. 31, 2023	5,369,466				5,369,466
Balance at Mar. 31, 2023	$ 332,076	74,199	(12,795)	[1]	$ 393,480
Exercise of stock options and vesting of restricted stock units (in shares)	20,074
Exercise of stock options and vesting of restricted stock units	$ 52				52
Tax withholding on vesting of restricted stock units (in shares)	(5,260)
Tax withholding on vesting of restricted stock units	$ (712)	0	0		(712)
Dividends paid, $0.16 per share		(859)			(859)
Stock-based compensation expense	$ 2,968				2,968
Foreign currency translation			(6,661)	[1]	(6,661)
Net (loss) income		(549)			(549)
Balance (in shares) at Jun. 30, 2023	5,384,280
Balance at Jun. 30, 2023	$ 334,384	72,791	(19,456)	[1]	$ 387,719
Balance (in shares) at Mar. 31, 2023	5,369,466				5,369,466
Balance at Mar. 31, 2023	$ 332,076	74,199	(12,795)	[1]	$ 393,480
Exercise of stock options and vesting of restricted stock units (in shares)					2,000
Balance (in shares) at Sep. 30, 2023	5,391,726				5,391,726
Balance at Sep. 30, 2023	$ 337,869	70,699	(20,809)	[1]	$ 387,759
Balance (in shares) at Jun. 30, 2023	5,384,280
Balance at Jun. 30, 2023	$ 334,384	72,791	(19,456)	[1]	387,719
Exercise of stock options and vesting of restricted stock units (in shares)	7,464
Exercise of stock options and vesting of restricted stock units	$ 304				304
Tax withholding on vesting of restricted stock units (in shares)	(18)
Tax withholding on vesting of restricted stock units	$ (2)				(2)
Dividends paid, $0.16 per share		(862)			(862)
Stock-based compensation expense	$ 3,183				3,183
Foreign currency translation			(1,353)		(1,353)
Net (loss) income		(1,230)			$ (1,230)
Balance (in shares) at Sep. 30, 2023	5,391,726				5,391,726
Balance at Sep. 30, 2023	$ 337,869	$ 70,699	$ (20,809)	[1]	$ 387,759
[1]Accumulated Other Comprehensive Income (Loss).

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parentheticals) - $ / shares	3 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Sep. 30, 2022	Jun. 30, 2022
Dividends paid, per share (in dollars per share)	$ 0.16	$ 0.16	$ 0.16	$ 0.16

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities:
Net (loss)	$ (1,230)	$ 1,306	$ (1,779)	$ (132)	$ (1,779)	$ (132)
Adjustments to reconcile net income to net cash from operating activities:
Depreciation and amortization			16,230	16,189
Stock-based compensation expense			6,151	7,803
Non-cash interest and debt amortization			461	452
Other			1,137	(1,544)
Cash from changes in operating assets and liabilities:
Accounts receivable, net			5,448	(2,657)
Inventories			(184)	(4,065)
Prepaid expenses and other assets			(3,528)	(3,052)
Accounts payable			(1,307)	243
Accrued liabilities and taxes payable			(1,743)	(5,869)
Unearned revenues			(1,171)	378
Net cash provided by operating activities			19,715	7,746
Cash flows from investing activities:
Purchases of property, plant and equipment			(904)	(1,864)
Net cash (used in) investing activities			(904)	(1,864)
Cash flows from financing activities:
Payments of debt			(13,000)	(22,000)
Dividends			(1,721)	(1,695)
Proceeds from the exercise of stock options			356	4,216
Payment of tax withholding obligation on vesting of restricted stock			(714)	(574)
Net cash (used in) financing activities			(15,079)	(20,053)
Effect of exchange rate changes on cash and cash equivalents			(1,025)	(2,798)
Net increase (decrease) in cash and cash equivalents			2,707	(16,969)
Cash and cash equivalents at beginning of period			32,910	49,346
Cash and cash equivalents at end of period	$ 35,617	$ 32,377	$ 35,617	$ 32,377	$ 35,617	$ 32,377

Note 1 - Description of Busines

Note 1 - Description of Business and Summary of Significant Accounting Policies	6 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]	Note 1 . Description of Business and Summary of Significant Accounting Policies Description of Business In this quarterly report on Form 10 We are a multinational manufacturer, developer, and seller of life science tools and critical quality control products and services, many of which are sold into niche markets driven by regulatory requirements. We have manufacturing operations in the United States and Europe, and our products are marketed by our sales personnel in North America, Europe, and Asia Pacific, and by independent distributors in these areas as well as throughout the rest of the world. We prefer markets in which we can establish a strong presence and achieve high gross profit margins. As of September 30, 2023 four ● Sterilization and Disinfection Control ● Clinical Genomics ● Biopharmaceutical Development ● Calibration Solutions Unallocated corporate expenses are reported within Corporate and Other. Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission and in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information. In the opinion of management, such unaudited information includes all adjustments, consisting of normal recurring adjustments necessary for the fair statement of our financial position and results of operations. The results of operations for the interim periods are not may not no 10 10 March 31, 2023 Our fiscal year ends on March 31. Prior Period Reclassifications Certain prior year amounts presented have been reclassified to conform with current presentation. The reclassifications have not 10 Risks and Uncertainties The preparation of financial statements requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities at the reporting date and revenues and expenses during the reporting periods. These estimates represent management's judgment about the outcome of future events. The global business environment continues to be impacted by cost pressure, the overall effects of economic uncertainty on customers' purchasing patterns, high interest rates, and other factors. It is not Recently Issued Accounting Pronouncements We have reviewed all recently issued accounting pronouncements and have concluded that they are either not not

Note 2 - Significant Transactio

Note 2 - Significant Transactions	6 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Significant Transactions [Text Block]	Note 2 . Significant Transactions Acquisition of GKE On October 14, 2023, Total cash consideration for the GKE acquisition was €85,000, €8,500 18 €5,000 7. October 16, 2023, Belyntic GmbH On November 17, 2022, During fiscal year 2023 , six September 30, 2023,

Note 3 - Revenue

Note 3 - Revenue	6 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	Note 3. We develop, manufacture, market, sell and maintain life sciences tools and quality control instruments and related consumables, and services. We evaluate revenues internally primarily based on operating segment and the nature of goods and services provided. Hardware sales include physical products such as instruments used for molecular and genetic analysis, protein synthesizers, medical meters, wireless sensor systems, and data loggers. Hardware sales may Consumables are typically used on a one We also offer maintenance, calibration, and testing service contracts. Under our service contracts we perform labor and replace parts on an as-needed basis over a contractually specified period of time, or perform specific, discrete services. Typically, revenue is recognized upon shipment of a product, upon completion of a discrete service, or over a period of time reflective of the performance period in the applicable contract, depending on when our obligation to the customer is satisfied. The significant majority of our revenues and related receivables are generated from contracts with customers that are 12 The following tables present disaggregated revenues for the three six September 30, 2023 September 30, 2022 Three Months Ended September 30, 2023 Sterilization and Disinfection Control Clinical Genomics Biopharmaceutical Development Calibration Solutions Total Consumables $ 14,749 $ 9,963 $ 4,187 $ 786 $ 29,685 Hardware and Software 120 4,474 2,475 6,884 13,953 Services 2,211 1,112 2,545 3,659 9,527 Total Revenues $ 17,080 $ 15,549 $ 9,207 $ 11,329 $ 53,165 Three Months Ended September 30, 2022 Sterilization and Disinfection Control Clinical Genomics Biopharmaceutical Development Calibration Solutions Total Consumables $ 14,704 $ 12,399 $ 4,000 $ 865 $ 31,968 Hardware and Software 218 4,394 5,988 5,980 16,580 Services 2,042 1,642 2,156 4,361 10,201 Total Revenues $ 16,964 $ 18,435 $ 12,144 $ 11,206 $ 58,749 Six Months Ended September 30, 2023 Sterilization and Disinfection Control Clinical Genomics Biopharmaceutical Development Calibration Solutions Total Consumables $ 28,456 $ 18,732 $ 8,673 $ 1,295 $ 57,156 Hardware and Software 201 7,901 5,166 13,962 27,230 Services 4,350 2,285 5,257 7,532 19,424 Total Revenues $ 33,007 $ 28,918 $ 19,096 $ 22,789 $ 103,810 Six Months Ended September 30, 2022 Sterilization and Disinfection Control Clinical Genomics Biopharmaceutical Development Calibration Solutions Total Consumables $ 26,932 $ 23,930 $ 7,664 $ 1,719 $ 60,245 Hardware and Software 524 5,885 10,812 11,673 28,894 Services 4,282 3,125 4,635 8,021 20,063 Total Revenues $ 31,738 $ 32,940 $ 23,111 $ 21,413 $ 109,202 Revenues from external customers are attributed to individual countries based upon the locations to which the products are shipped or exported, or locations where services are performed, as follows: Three Months Ended September 30, Six Months Ended September 30, 2023 2022 2023 2022 United States $ 27,073 $ 30,989 $ 53,610 $ 60,111 China 7,529 7,480 13,642 11,177 Other 18,563 20,280 36,558 37,914 Total revenues $ 53,165 $ 58,749 $ 103,810 $ 109,202 Other than China, no 10% three six September 30, 2023 2022 Contract Balances Our contracts have varying payment terms and conditions. Some customers prepay for products and services, resulting in unearned revenues or customer deposits, called contract liabilities. Short-term contract liabilities are included within unearned revenues in the accompanying Condensed Consolidated Balance Sheets, and long-term contract liabilities are included within other long-term liabilities in the accompanying Condensed Consolidated Balance Sheets. A summary of contract liabilities is as follows: Contract liabilities as of March 31, 2023 $ 16,098 Prior year contract liabilities recognized in revenues during the six months ended September 30, 2023 (6,399 ) Contract liabilities added during the six months ended September 30, 2023, net of revenues recognized 4,934 Contract liabilities balance as of September 30, 2023 $ 14,633 Contract liabilities primarily relate to service contracts with original expected service durations of 12

Note 4 - Fair Value Measurement

Note 4 - Fair Value Measurements	6 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Fair Value Disclosures [Text Block]	Note 4. Our financial instruments consist primarily of cash and cash equivalents, trade accounts receivable, obligations under trade accounts payable, and debt. Due to their short-term nature, the carrying values for cash and cash equivalents, trade accounts receivable, and trade accounts payable approximate fair value; they are classified within Level 1 Historically, the financial instruments that subject us to the highest concentration of credit risk are cash and cash equivalents and accounts receivable. We maintain relationships and cash deposits at multiple banking institutions across the world in an effort to diversify and reduce risk of loss. Concentration of credit risk with respect to accounts receivable is limited to customers to whom we make significant sales. No customers accounted for more than 10% September 30, 2023 We record an allowance for potential uncollectible amounts against our accounts receivable using historical collection experience and current and expected future economic and market conditions. To manage credit risk, we consider the creditworthiness of new and existing customers, and we regularly review outstanding balances and payment histories. We may may We have outstanding $172,500 aggregate principal amount of 1.375% convertible senior notes due August 15, 2025 ( 2 The estimated fair value and carrying value of the Notes was as follows: September 30, 2023 March 31, 2023 Carrying Value Fair Value (Level 2) Carrying Value Fair Value (Level 2) Notes $ 170,733 $ 155,681 $ 170,272 $ 161,072 We are obligated to pay contingent consideration of $1,500 cash related to the Belyntic acquisition upon approval of pending patent applications. We estimate the fair value of the contingent consideration using a probability-weighted outcome analysis based on our expectations of patent approval, leveraging our historical experience and expert input, and we adjust the estimated fair value at each reporting period through earnings. The fair value of the contingent consideration was $1,180 as of September 30, 2023 first October 18, 2023, one September 30, 2023 Amounts recognized or disclosed at fair value in the unaudited condensed consolidated financial statements on a nonrecurring basis include the initial recognition and disclosure of most assets and liabilities purchased in business acquisitions and any related measurement period adjustments. Additionally, assets such as property and equipment, operating lease assets, goodwill, and other intangible assets are adjusted to fair value if determined to be impaired. We recorded no three six September 30, 2023 2022 3 There were no three six September 30, 2023 2022

Note 5 - Supplemental Balance S

Note 5 - Supplemental Balance Sheets Information	6 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Supplemental Balance Sheet Disclosures [Text Block]	Note 5. Inventories consisted of the following: September 30, 2023 March 31, 2023 Raw materials $ 20,203 $ 20,064 Work in process 633 617 Finished goods 12,043 13,961 Total inventories $ 32,879 $ 34,642 The decrease in inventories is primarily attributable to non-cash scrap expense and transfers of instruments to be used in our business from inventory to fixed assets, partially offset by inventory purchases to meet current production needs. Prepaid expenses and other current assets consisted of the following: September 30, 2023 March 31, 2023 Prepaid expenses $ 3,494 $ 2,498 Deposits 1,563 1,376 Prepaid income taxes 3,534 953 Other current assets 4,235 4,045 Total prepaid expenses and other $ 12,826 $ 8,872 Accrued payroll and benefits consisted of the following: September 30, 2023 March 31, 2023 Bonus payable $ 3,317 $ 4,461 Wages and paid-time-off payable 2,139 2,329 Payroll related taxes 1,854 1,982 Other benefits payable 1,043 661 Total accrued payroll and benefits $ 8,353 $ 9,433 Other accrued expenses consisted of the following: September 30, 2023 March 31, 2023 Accrued business taxes $ 6,079 $ 5,941 Current operating lease liabilities 2,784 2,868 Income taxes payable 343 992 Other 3,131 2,297 Total other accrued expenses $ 12,337 $ 12,098

Note 6 - Goodwill and Intangibl

Note 6 - Goodwill and Intangible Assets, Net	6 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	Note 6. Intangible assets, the significant majority of which are finite-lived, consisted of the following: September 30, 2023 March 31, 2023 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Customer relationships $ 231,543 $ (94,486 ) $ 137,057 $ 238,247 $ (86,058 ) $ 152,189 Intellectual property 66,576 (23,160 ) 43,416 65,950 (19,550 ) 46,400 Other intangibles 24,437 (7,230 ) 17,207 24,793 (6,567 ) 18,226 Total $ 322,556 $ (124,876 ) $ 197,680 $ 328,990 $ (112,175 ) $ 216,815 Amortization expense for finite-lived intangible assets acquired in a business combination was as follows: Three Months Ended September 30, Six Months Ended September 30, 2023 2022 2023 2022 Amortization in cost of revenues $ 1,756 $ 1,691 $ 3,484 $ 3,399 Amortization in general and administrative 5,429 5,415 10,921 11,027 Total $ 7,185 $ 7,106 $ 14,405 $ 14,426 For the following fiscal years ending March 31, Remainder of 2024 $ 13,803 2025 26,523 2026 25,765 2027 25,270 2028 24,825 The change in the carrying amount of goodwill was as follows: Sterilization and Disinfection Control Clinical Genomics Biopharmaceutical Development Calibration Solutions Total March 31, 2023 $ 29,559 $ 135,811 $ 83,857 $ 37,217 286,444 Effect of foreign currency translation (201 ) (180 ) (3,612 ) (24 ) (4,017 ) Measurement period adjustment - Belyntic Acquisition - - 841 - 841 September 30, 2023 $ 29,358 $ 135,631 $ 81,086 $ 37,193 $ 283,268 Goodwill in the Biopharmaceutical Development division related to the Belyntic acquisition is tax deductible.

Note 7 - Indebtedness

Note 7 - Indebtedness	6 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 7 . Indebtedness Credit Facility As of September 30, 2023 four 1 2 not 3 not March 2025. September 30, 2023 The financial covenants in the Credit Facility include a maximum leverage ratio of 4.5 to 1.0 September 30, 2023 may 1.0 four 1.0. September 30, 2023 Amounts borrowed under the Credit Facility bear interest at either a base rate or a SOFR rate plus an applicable spread. We are obligated to pay quarterly unused commitment fees of between 0.15% and 0.35% of the Credit Facility’s aggregate principal amount, based on our leverage ratio. On October 5, 2023, October 11, 2023, 2. Convert ible Notes On August 12, 2019, August 15, 2025, February 15 August 15 $ 1,000 Upon conversion, we will pay or deliver, as the case may not three six September 30, 2023 September 30, 2023 not September 30, 2023 The net carrying amount of the Notes was as follows: September 30, 2023 March 31, 2023 Principal outstanding $ 172,500 $ 172,500 Unamortized debt issuance costs (1,767 ) (2,228 ) Net carrying value $ 170,733 $ 170,272 We recognized interest expense on the Notes as follows: Three Months Ended September 30, Six Months Ended September 30, 2023 2022 2023 2022 Coupon interest expense at 1.375% $ 593 $ 593 $ 1,186 $ 1,186 Amortization of debt issuance costs 231 227 461 452 Total interest and amortization of debt issuance costs $ 824 $ 820 $ 1,647 $ 1,638 The effective interest rate on the notes is approximately 1.9%.

Note 8 - Stockholders' Equity

Note 8 - Stockholders' Equity	6 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	Note 8 . Stockholders' Equity Stock-Based Compensation During the six September 30, 2023 2021 "2021 660 Expense recognized related to stock-based compensation is as follows: Three Months Ended September 30, Six Months Ended September 30, 2023 2022 2023 2022 Stock-based compensation expense $ 3,183 $ 4,371 $ 6,151 $ 7,803 Amount of income tax expense (benefit) recognized in earnings 1,389 (89 ) 517 (2,081 ) Stock-based compensation expense, net of tax $ 4,572 $ 4,282 $ 6,668 $ 5,722 Stock-based compensation expense is included in cost of revenues, selling, general and administrative, and research and development expense in the accompanying unaudited Condensed Consolidated Statements of Operations. The following is a summary of stock option award activity for the six September 30, 2023 Stock Options Shares Subject to Options Weighted- Average Exercise Price per Share Weighted-Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding as of March 31, 2023 163 $ 200.62 3.3 $ 1,643 Awards granted 53 131.67 Awards forfeited or expired (15 ) 213.22 Awards exercised (2 ) 132.40 Outstanding as of September 30, 2023 199 $ 181.90 3.7 $ - The stock options granted during the six September 30, 2023 third The following is a summary of RSU and PSU award activity for the six September 30, 2023 Time-Based Restricted Stock Units Performance-Based Restricted Stock Units Number of Shares Weighted- Average Grant Date Fair Value per Share Number of Shares Weighted- Average Grant Date Fair Value per Share Outstanding as of March 31, 2023 (1) 57 $ 209.27 44 $ 286.02 Awards granted (1) 53 134.35 32 132.29 Awards forfeited (3 ) 179.82 - - Awards distributed (25 ) 208.33 - - Outstanding as of September 30, 2023 (1) 82 $ 162.48 76 $ 223.07 ( 1 Balances for PSUs are reflected at target. Outstanding time-based RSUs vest and settle in shares of our common stock on a one one six September 30, 2023 third six September 30, 2023 September 1, 2024, June 21, 2025 June 21, 2026. six September 30, 2023 one We grant PSUs to certain key employees. The number of shares earned is determined at the end of each performance period based on Mesa's achievement of certain pre-defined targets defined in the related award agreement. PSUs vest upon completion of the service period described in the award agreement. We recognize the expense relating to the performance-based RSUs based on the probable outcome of achievement of the performance targets on a straight-line basis over the service period. During the six September 30, 2023 "FY24 April 1, 2023 June 21, 2026. April 1, 2023 March 31, 2024. not no April 1, 2023 March 31, 2026.

Note 9 - Net (Loss) Earnings Pe

Note 9 - Net (Loss) Earnings Per Share	6 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Earnings Per Share [Text Block]	Note 9 . Net (Loss) Earnings Per Share Basic net (loss) earnings per share is computed by dividing net (loss) income by the weighted-average number of common shares outstanding during the reporting period. Diluted (loss) earnings per share (“diluted EPS”) is computed similarly to basic (loss) earnings per share, except that it includes the potential dilution that could occur if dilutive securities were exercised. Potentially dilutive securities include stock options and both time and performance based RSUs (collectively “stock awards”), as well as common shares underlying our Notes. Stock awards are excluded from the calculation of diluted EPS if they are subject to performance conditions that have not not The impact of the assumed conversion of the Notes calculated under the if-converted method was antidilutive, and as such, shares underlying the Notes were excluded from the diluted EPS calculation for the three six September 30, 2023 September 30, 2022. The following table presents a reconciliation of the denominators used in the computation of basic and diluted (loss) earnings per share: Three Months Ended September 30, Six Months Ended September 30, 2023 2022 2023 2022 Net (loss) income $ (1,230 ) $ 1,306 $ (1,779 ) $ (132 ) Weighted average outstanding shares of common stock 5,387 5,323 5,379 5,298 Dilutive effect of stock options - 27 - - Dilutive effect of RSUs - 14 - - Fully diluted shares 5,387 5,364 5,379 5,298 Basic (loss) earnings per share $ (0.23 ) $ 0.25 $ (0.33 ) $ (0.02 ) Diluted (loss) earnings per share $ (0.23 ) $ 0.24 $ (0.33 ) $ (0.02 ) The following stock awards were excluded from the calculation of diluted EPS: Three Months Ended September 30, Six Months Ended September 30, 2023 2022 2023 2022 Assumed conversion of the Notes 608 608 608 608 Stock awards that were anti-dilutive 282 154 255 328 Stock awards subject to performance and market conditions 43 60 41 52 Total stock awards excluded from diluted EPS 933 822 904 988

Note 10 - Income Taxes

Note 10 - Income Taxes	6 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 10 . Income Taxes For interim income tax reporting, we estimate our annual effective tax rate and apply this effective tax rate to our year-to-date pre-tax income. Each quarter, our estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. Additionally, the tax effects of significant unusual or infrequently occurring items are recognized as discrete items in the interim period in which the events occur. There is a potential for volatility in the effective tax rate due to several factors, including changes in the mix of the pre-tax income and the jurisdictions to which they relate, changes in tax laws and foreign tax holidays, settlement with taxing authorities, and foreign currency fluctuations. Our effective income tax rate was 21.4% for the six September 30, 2023 six September 30, 2022. six September 30, 2023 six September 30, 2023

Note 11 - Commitments and Conti

Note 11 - Commitments and Contingencies	6 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 11 . Commitments and Contingencies We review the adequacy of our legal reserves on a quarterly basis and establish reserves for loss contingencies that are both probable and reasonably estimable. As of September 30, 2023 no As part of the Belyntic acquisition, we have agreed to pay $1,500 to the sellers if contractually specified patents are issued. Effective October 18, 2023, 12 As part of the GKE acquisition consummated on October 14, 2023, €8,500 18 may €5,000

Note 12 - Segment Information

Note 12 - Segment Information	6 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	Note 12 . S egment Information The following tables set forth our segment information: Three Months Ended September 30, Six Months Ended September 30, 2023 2022 2023 2022 Revenues: Sterilization and Disinfection Control $ 17,080 $ 16,964 $ 33,007 $ 31,738 Clinical Genomics 15,549 18,435 28,918 32,940 Biopharmaceutical Development 9,207 12,144 19,096 23,111 Calibration Solutions 11,329 11,206 22,789 21,413 Total revenues (a) $ 53,165 $ 58,749 $ 103,810 $ 109,202 Gross profit: Sterilization and Disinfection Control $ 12,476 $ 12,199 $ 24,067 $ 22,967 Clinical Genomics 7,727 10,641 14,455 18,490 Biopharmaceutical Development 5,509 7,557 11,942 14,634 Calibration Solutions 6,407 6,007 12,838 11,671 Reportable segment gross profit 32,119 36,404 63,302 67,762 Corporate and Other (b) (10 ) (18 ) (10 ) (35 ) Gross profit $ 32,109 $ 36,386 $ 63,292 $ 67,727 Reconciling Items: Operating expense 32,169 32,391 64,016 68,326 Operating (loss) income (60 ) 3,995 (724 ) (599 ) Nonoperating expense, net 1,265 611 1,538 1,429 (Loss) earnings before income taxes $ (1,325 ) $ 3,384 $ (2,262 ) $ (2,028 ) (a) Intersegment revenues are not (b) Unallocated corporate expenses are reported within Corporate and Other. The following table sets forth inventories by reportable segment. Our chief operating decision maker is not September 30, March 31, 2023 2023 Sterilization and Disinfection Control $ 3,889 $ 3,492 Clinical Genomics 11,330 13,985 Biopharmaceutical Development 8,541 8,384 Calibration Solutions 9,119 8,781 Total inventories $ 32,879 $ 34,642

Insider Trading Arrangements

Insider Trading Arrangements	6 Months Ended
	Sep. 30, 2023 shares
ecd_TradingArrByIndTable
Material Terms of Trading Arrangement [Text Block]	5. Other Information The 10b5 1 Director John Schmieder entered into a trading arrangement on June 14, 2023. September 15, 2023. Chief Financial Officer John Sakys entered into a trading arrangement on August 23, 2023. April 2, 2024. may Senior Vice President of Continuous Improvement Brian Archbold entered into a trading arrangement on September 14, 2023. April 2, 2024. may may
Rule 10b5-1 Arrangement Adopted [Flag]	true
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	true
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false
John Schmieder [Member]
ecd_TradingArrByIndTable
Trading Arrangement, Individual Title	Director
Trading Arrangement, Individual Name	John Schmieder
Trading Arrangement Adoption Date	June 14, 2023
Trading Arrangement Termination Date	September 15, 2023
Trading Arrangement, Securities Aggregate Available Amount	7,000
John Sakys [Member]
ecd_TradingArrByIndTable
Trading Arrangement, Individual Title	Chief Financial Officer
Trading Arrangement, Individual Name	John Sakys
Trading Arrangement Adoption Date	August 23, 2023
Trading Arrangement Termination Date	April 2, 2024.
Trading Arrangement, Securities Aggregate Available Amount	2,500
Brian Archbold [Member]
ecd_TradingArrByIndTable
Trading Arrangement, Individual Title	Senior Vice President of Continuous Improvement
Trading Arrangement, Individual Name	Brian Archbold
Trading Arrangement Adoption Date	September 14, 2023
Trading Arrangement Termination Date	April 2, 2024
Brian Archbold [Member] | Trading Arrangement 1 [Member]
ecd_TradingArrByIndTable
Trading Arrangement, Securities Aggregate Available Amount	710
Brian Archbold [Member] | Trading Arrangement 2 [Member]
ecd_TradingArrByIndTable
Trading Arrangement, Securities Aggregate Available Amount	1,500

Significant Accounting Policies

Significant Accounting Policies (Policies)	6 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Description of Business [Policy Text Block]	Description of Business In this quarterly report on Form 10 We are a multinational manufacturer, developer, and seller of life science tools and critical quality control products and services, many of which are sold into niche markets driven by regulatory requirements. We have manufacturing operations in the United States and Europe, and our products are marketed by our sales personnel in North America, Europe, and Asia Pacific, and by independent distributors in these areas as well as throughout the rest of the world. We prefer markets in which we can establish a strong presence and achieve high gross profit margins. As of September 30, 2023 four ● Sterilization and Disinfection Control ● Clinical Genomics ● Biopharmaceutical Development ● Calibration Solutions Unallocated corporate expenses are reported within Corporate and Other.
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission and in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information. In the opinion of management, such unaudited information includes all adjustments, consisting of normal recurring adjustments necessary for the fair statement of our financial position and results of operations. The results of operations for the interim periods are not may not no 10 10 March 31, 2023 Our fiscal year ends on March 31.
Reclassification, Comparability Adjustment [Policy Text Block]	Prior Period Reclassifications Certain prior year amounts presented have been reclassified to conform with current presentation. The reclassifications have not 10
Risk and Uncertainties, Policy [Policy Text Block]	Risks and Uncertainties The preparation of financial statements requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities at the reporting date and revenues and expenses during the reporting periods. These estimates represent management's judgment about the outcome of future events. The global business environment continues to be impacted by cost pressure, the overall effects of economic uncertainty on customers' purchasing patterns, high interest rates, and other factors. It is not
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements We have reviewed all recently issued accounting pronouncements and have concluded that they are either not not

Note 3 - Revenue (Tables)

Note 3 - Revenue (Tables)	6 Months Ended
	Sep. 30, 2023
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended September 30, 2023 Sterilization and Disinfection Control Clinical Genomics Biopharmaceutical Development Calibration Solutions Total Consumables $ 14,749 $ 9,963 $ 4,187 $ 786 $ 29,685 Hardware and Software 120 4,474 2,475 6,884 13,953 Services 2,211 1,112 2,545 3,659 9,527 Total Revenues $ 17,080 $ 15,549 $ 9,207 $ 11,329 $ 53,165 Three Months Ended September 30, 2022 Sterilization and Disinfection Control Clinical Genomics Biopharmaceutical Development Calibration Solutions Total Consumables $ 14,704 $ 12,399 $ 4,000 $ 865 $ 31,968 Hardware and Software 218 4,394 5,988 5,980 16,580 Services 2,042 1,642 2,156 4,361 10,201 Total Revenues $ 16,964 $ 18,435 $ 12,144 $ 11,206 $ 58,749 Six Months Ended September 30, 2023 Sterilization and Disinfection Control Clinical Genomics Biopharmaceutical Development Calibration Solutions Total Consumables $ 28,456 $ 18,732 $ 8,673 $ 1,295 $ 57,156 Hardware and Software 201 7,901 5,166 13,962 27,230 Services 4,350 2,285 5,257 7,532 19,424 Total Revenues $ 33,007 $ 28,918 $ 19,096 $ 22,789 $ 103,810 Six Months Ended September 30, 2022 Sterilization and Disinfection Control Clinical Genomics Biopharmaceutical Development Calibration Solutions Total Consumables $ 26,932 $ 23,930 $ 7,664 $ 1,719 $ 60,245 Hardware and Software 524 5,885 10,812 11,673 28,894 Services 4,282 3,125 4,635 8,021 20,063 Total Revenues $ 31,738 $ 32,940 $ 23,111 $ 21,413 $ 109,202
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]	Three Months Ended September 30, Six Months Ended September 30, 2023 2022 2023 2022 United States $ 27,073 $ 30,989 $ 53,610 $ 60,111 China 7,529 7,480 13,642 11,177 Other 18,563 20,280 36,558 37,914 Total revenues $ 53,165 $ 58,749 $ 103,810 $ 109,202
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]	Contract liabilities as of March 31, 2023 $ 16,098 Prior year contract liabilities recognized in revenues during the six months ended September 30, 2023 (6,399 ) Contract liabilities added during the six months ended September 30, 2023, net of revenues recognized 4,934 Contract liabilities balance as of September 30, 2023 $ 14,633

Note 4 - Fair Value Measureme_2

Note 4 - Fair Value Measurements (Tables)	6 Months Ended
	Sep. 30, 2023
Notes Tables
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]	September 30, 2023 March 31, 2023 Carrying Value Fair Value (Level 2) Carrying Value Fair Value (Level 2) Notes $ 170,733 $ 155,681 $ 170,272 $ 161,072

Note 5 - Supplemental Balance_2

Note 5 - Supplemental Balance Sheets Information (Tables)	6 Months Ended
	Sep. 30, 2023
Notes Tables
Schedule of Inventory, Current [Table Text Block]	September 30, 2023 March 31, 2023 Raw materials $ 20,203 $ 20,064 Work in process 633 617 Finished goods 12,043 13,961 Total inventories $ 32,879 $ 34,642
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	September 30, 2023 March 31, 2023 Prepaid expenses $ 3,494 $ 2,498 Deposits 1,563 1,376 Prepaid income taxes 3,534 953 Other current assets 4,235 4,045 Total prepaid expenses and other $ 12,826 $ 8,872
Schedule of Employee Related Liabilities [Table Text Block]	September 30, 2023 March 31, 2023 Bonus payable $ 3,317 $ 4,461 Wages and paid-time-off payable 2,139 2,329 Payroll related taxes 1,854 1,982 Other benefits payable 1,043 661 Total accrued payroll and benefits $ 8,353 $ 9,433
Schedule of Accrued Liabilities [Table Text Block]	September 30, 2023 March 31, 2023 Accrued business taxes $ 6,079 $ 5,941 Current operating lease liabilities 2,784 2,868 Income taxes payable 343 992 Other 3,131 2,297 Total other accrued expenses $ 12,337 $ 12,098

Note 6 - Goodwill and Intangi_2

Note 6 - Goodwill and Intangible Assets, Net (Tables)	6 Months Ended
	Sep. 30, 2023
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	September 30, 2023 March 31, 2023 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Customer relationships $ 231,543 $ (94,486 ) $ 137,057 $ 238,247 $ (86,058 ) $ 152,189 Intellectual property 66,576 (23,160 ) 43,416 65,950 (19,550 ) 46,400 Other intangibles 24,437 (7,230 ) 17,207 24,793 (6,567 ) 18,226 Total $ 322,556 $ (124,876 ) $ 197,680 $ 328,990 $ (112,175 ) $ 216,815
Finite-Lived Intangible Assets Amortization Expense [Table Text Block]	Three Months Ended September 30, Six Months Ended September 30, 2023 2022 2023 2022 Amortization in cost of revenues $ 1,756 $ 1,691 $ 3,484 $ 3,399 Amortization in general and administrative 5,429 5,415 10,921 11,027 Total $ 7,185 $ 7,106 $ 14,405 $ 14,426
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Remainder of 2024 $ 13,803 2025 26,523 2026 25,765 2027 25,270 2028 24,825
Schedule of Goodwill [Table Text Block]	Sterilization and Disinfection Control Clinical Genomics Biopharmaceutical Development Calibration Solutions Total March 31, 2023 $ 29,559 $ 135,811 $ 83,857 $ 37,217 286,444 Effect of foreign currency translation (201 ) (180 ) (3,612 ) (24 ) (4,017 ) Measurement period adjustment - Belyntic Acquisition - - 841 - 841 September 30, 2023 $ 29,358 $ 135,631 $ 81,086 $ 37,193 $ 283,268

Note 7 - Indebtedness (Tables)

Note 7 - Indebtedness (Tables)	6 Months Ended
	Sep. 30, 2023
Notes Tables
Convertible Debt [Table Text Block]	September 30, 2023 March 31, 2023 Principal outstanding $ 172,500 $ 172,500 Unamortized debt issuance costs (1,767 ) (2,228 ) Net carrying value $ 170,733 $ 170,272
Interest Expense on Convertible Debt [Table Text Block]	Three Months Ended September 30, Six Months Ended September 30, 2023 2022 2023 2022 Coupon interest expense at 1.375% $ 593 $ 593 $ 1,186 $ 1,186 Amortization of debt issuance costs 231 227 461 452 Total interest and amortization of debt issuance costs $ 824 $ 820 $ 1,647 $ 1,638

Note 8 - Stockholders' Equity (

Note 8 - Stockholders' Equity (Tables)	6 Months Ended
	Sep. 30, 2023
Notes Tables
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended September 30, Six Months Ended September 30, 2023 2022 2023 2022 Stock-based compensation expense $ 3,183 $ 4,371 $ 6,151 $ 7,803 Amount of income tax expense (benefit) recognized in earnings 1,389 (89 ) 517 (2,081 ) Stock-based compensation expense, net of tax $ 4,572 $ 4,282 $ 6,668 $ 5,722
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Stock Options Shares Subject to Options Weighted- Average Exercise Price per Share Weighted-Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Outstanding as of March 31, 2023 163 $ 200.62 3.3 $ 1,643 Awards granted 53 131.67 Awards forfeited or expired (15 ) 213.22 Awards exercised (2 ) 132.40 Outstanding as of September 30, 2023 199 $ 181.90 3.7 $ -
Share-Based Payment Arrangement, Activity [Table Text Block]	Time-Based Restricted Stock Units Performance-Based Restricted Stock Units Number of Shares Weighted- Average Grant Date Fair Value per Share Number of Shares Weighted- Average Grant Date Fair Value per Share Outstanding as of March 31, 2023 (1) 57 $ 209.27 44 $ 286.02 Awards granted (1) 53 134.35 32 132.29 Awards forfeited (3 ) 179.82 - - Awards distributed (25 ) 208.33 - - Outstanding as of September 30, 2023 (1) 82 $ 162.48 76 $ 223.07

Note 9 - Net (Loss) Earnings _2

Note 9 - Net (Loss) Earnings Per Share (Tables)	6 Months Ended
	Sep. 30, 2023
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended September 30, Six Months Ended September 30, 2023 2022 2023 2022 Net (loss) income $ (1,230 ) $ 1,306 $ (1,779 ) $ (132 ) Weighted average outstanding shares of common stock 5,387 5,323 5,379 5,298 Dilutive effect of stock options - 27 - - Dilutive effect of RSUs - 14 - - Fully diluted shares 5,387 5,364 5,379 5,298 Basic (loss) earnings per share $ (0.23 ) $ 0.25 $ (0.33 ) $ (0.02 ) Diluted (loss) earnings per share $ (0.23 ) $ 0.24 $ (0.33 ) $ (0.02 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended September 30, Six Months Ended September 30, 2023 2022 2023 2022 Assumed conversion of the Notes 608 608 608 608 Stock awards that were anti-dilutive 282 154 255 328 Stock awards subject to performance and market conditions 43 60 41 52 Total stock awards excluded from diluted EPS 933 822 904 988

Note 12 - Segment Information (

Note 12 - Segment Information (Tables)	6 Months Ended
	Sep. 30, 2023
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Three Months Ended September 30, Six Months Ended September 30, 2023 2022 2023 2022 Revenues: Sterilization and Disinfection Control $ 17,080 $ 16,964 $ 33,007 $ 31,738 Clinical Genomics 15,549 18,435 28,918 32,940 Biopharmaceutical Development 9,207 12,144 19,096 23,111 Calibration Solutions 11,329 11,206 22,789 21,413 Total revenues (a) $ 53,165 $ 58,749 $ 103,810 $ 109,202 Gross profit: Sterilization and Disinfection Control $ 12,476 $ 12,199 $ 24,067 $ 22,967 Clinical Genomics 7,727 10,641 14,455 18,490 Biopharmaceutical Development 5,509 7,557 11,942 14,634 Calibration Solutions 6,407 6,007 12,838 11,671 Reportable segment gross profit 32,119 36,404 63,302 67,762 Corporate and Other (b) (10 ) (18 ) (10 ) (35 ) Gross profit $ 32,109 $ 36,386 $ 63,292 $ 67,727 Reconciling Items: Operating expense 32,169 32,391 64,016 68,326 Operating (loss) income (60 ) 3,995 (724 ) (599 ) Nonoperating expense, net 1,265 611 1,538 1,429 (Loss) earnings before income taxes $ (1,325 ) $ 3,384 $ (2,262 ) $ (2,028 )
Schedule of Segment Reporting Information, by Inventory Segment [Table Text Block]	September 30, March 31, 2023 2023 Sterilization and Disinfection Control $ 3,889 $ 3,492 Clinical Genomics 11,330 13,985 Biopharmaceutical Development 8,541 8,384 Calibration Solutions 9,119 8,781 Total inventories $ 32,879 $ 34,642

Note 2 - Significant Transact_2

Note 2 - Significant Transactions (Details Textual) $ in Thousands, € in Millions	Oct. 14, 2023 USD ($)	Oct. 14, 2023 EUR (€)	Nov. 17, 2022 USD ($)
GKE Acquisition [Member] | Subsequent Event [Member]
Business Combination, Consideration Transferred | €		€ 85
Business Combination, Consideration Transferred, Liabilities Incurred | €		8.5
Business Combination, Consideration Transferred, Contingent Consideration Liability | €		€ 5
Proceeds from Lines of Credit	$ 65,000
GKE Acquisition [Member] | GKE GmbH and SAL GmbH [Member] | Subsequent Event [Member]
Business Acquisition, Percentage of Voting Interests Acquired	100%	100%
GKE Acquisition [Member] | Beijing GKE Science & Technology Co. Ltd. [Member] | Subsequent Event [Member]
Business Acquisition, Percentage of Voting Interests Acquired	100%	100%
Belyntic Acquisition [Member]
Business Combination, Consideration Transferred			$ 6,450
Payments to Acquire Businesses, Gross			4,950
Business Combination, Contingent Consideration, Liability			$ 1,500

Note 3 - Revenue - Disaggregati

Note 3 - Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Thousands		3 Months Ended				6 Months Ended				9 Months Ended
		Sep. 30, 2023		Sep. 30, 2022		Sep. 30, 2023		Sep. 30, 2022		Sep. 30, 2023		Sep. 30, 2022
Revenues		$ 53,165		$ 58,749		$ 103,810		$ 109,202		$ 103,810		$ 109,202
Consumables [Member] | Transferred at Point in Time [Member]
Revenues		29,685		31,968		57,156		60,245
Hardware and Software [Member] | Transferred at Point in Time [Member]
Revenues		13,953		16,580		27,230		28,894
Service [Member] | Transferred at Point in Time [Member]
Revenues		9,527		10,201		19,424		20,063
Operating Segments [Member] | Sterilization and Disinfection Control [Member]
Revenues		17,080	[1]	16,964	[1]	33,007		31,738		33,007	[1]	31,738	[1]
Operating Segments [Member] | Clinical Genomics [Member]
Revenues		15,549	[1]	18,435	[1]	28,918		32,940		28,918	[1]	32,940	[1]
Operating Segments [Member] | Biopharmaceutical Development [Member]
Revenues		9,207	[1]	12,144	[1]	19,096		23,111		19,096	[1]	23,111	[1]
Operating Segments [Member] | Calibration Solutions [Member]
Revenues		11,329	[1],[2]	11,206	[1],[2]	22,789	[2]	21,413	[2]	$ 22,789	[1]	$ 21,413	[1]
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Sterilization and Disinfection Control [Member]
Revenues		14,749		14,704		28,456		26,932
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Clinical Genomics [Member]
Revenues		9,963		12,399		18,732		23,930
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Biopharmaceutical Development [Member]
Revenues		4,187		4,000		8,673		7,664
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Calibration Solutions [Member]
Revenues		786		865		1,295		1,719
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Sterilization and Disinfection Control [Member]
Revenues		120		218		201		524
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Clinical Genomics [Member]
Revenues		4,474		4,394		7,901		5,885
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Biopharmaceutical Development [Member]
Revenues		2,475		5,988		5,166		10,812
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Calibration Solutions [Member]
Revenues	[2]	6,884		5,980		13,962		11,673
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Sterilization and Disinfection Control [Member]
Revenues		2,211		2,042		4,350		4,282
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Clinical Genomics [Member]
Revenues		1,112		1,642		2,285		3,125
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Biopharmaceutical Development [Member]
Revenues		2,545		2,156		5,257		4,635
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Calibration Solutions [Member]
Revenues	[2]	$ 3,659		$ 4,361		$ 7,532		$ 8,021
[1]Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.[2]Revenues in the Clinical Genomics division represent transactions subsequent to the Agena Acquisition on October 20, 2021.

Note 3 - Revenue Recognition -

Note 3 - Revenue Recognition - Revenues From External Customers (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenues	$ 53,165	$ 58,749	$ 103,810	$ 109,202	$ 103,810	$ 109,202
UNITED STATES
Revenues	27,073	30,989	53,610	60,111
CHINA
Revenues	7,529	7,480	13,642	11,177
Other [Member]
Revenues	$ 18,563	$ 20,280	$ 36,558	$ 37,914

Note 3 - Revenue - Contract Lia

Note 3 - Revenue - Contract Liabilities (Details) $ in Thousands	6 Months Ended
	Sep. 30, 2023 USD ($)
Contract liabilities, balance	$ 16,098
Prior year contract liabilities recognized in revenues during the six months ended September 30, 2023	(6,399)
Contract liabilities added during the six months ended September 30, 2023, net of revenues recognized	4,934
Contract liabilities, balance	$ 14,633

Note 4 - Fair Value Measureme_3

Note 4 - Fair Value Measurements (Details Textual) $ in Thousands	6 Months Ended
	Sep. 30, 2023 USD ($)	Mar. 31, 2023 USD ($)	Nov. 17, 2022 USD ($)	Aug. 12, 2019
Belyntic Acquisition [Member] | Other Long-term Liabilities [Member]
Business Combination, Contingent Consideration, Liability, Noncurrent	$ 1,180		$ 1,500
Senior Notes [Member] | The Notes [Member]
Long-term Debt, Gross	$ 172,500	$ 172,500
Debt Instrument, Interest Rate, Stated Percentage	1.375%			1.375%
Accounts Receivable [Member] | Customer Concentration Risk [Member]
Number of Major Customers	0

Note 4 - Fair Value Measureme_4

Note 4 - Fair Value Measurements - Fair Value and Carrying Value of the Notes (Details) - Senior Notes [Member] - USD ($) $ in Thousands	Sep. 30, 2023	Mar. 31, 2023
Reported Value Measurement [Member]
Notes	$ 170,733	$ 170,272
Estimate of Fair Value Measurement [Member] | Fair Value, Inputs, Level 2 [Member]
Notes	$ 155,681	$ 161,072

Note 5 - Supplemental Balance_3

Note 5 - Supplemental Balance Sheets Information - Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Mar. 31, 2023
Raw materials	$ 20,203	$ 20,064
Work in process	633	617
Finished goods	12,043	13,961
Total inventories	$ 32,879	$ 34,642

Note 5 - Supplemental Balance_4

Note 5 - Supplemental Balance Sheets Information - Prepaid and Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Mar. 31, 2023
Prepaid expenses	$ 3,494	$ 2,498
Deposits	1,563	1,376
Prepaid income taxes	3,534	953
Other current assets	4,235	4,045
Total prepaid expenses and other	$ 12,826	$ 8,872

Note 5 - Supplemental Balance_5

Note 5 - Supplemental Balance Sheets Information - Accrued Payroll and Benefits (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Mar. 31, 2023
Bonus payable	$ 3,317	$ 4,461
Wages and paid-time-off payable	2,139	2,329
Payroll related taxes	1,854	1,982
Other benefits payable	1,043	661
Total accrued payroll and benefits	$ 8,353	$ 9,433

Note 5 - Supplemental Balance_6

Note 5 - Supplemental Balance Sheets Information - Other Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Mar. 31, 2023
Current operating lease liabilities	$ 2,784	$ 2,868
Income taxes payable	343	992
Other	3,131	2,297
Total other accrued expenses	12,337	12,098
Other Accrued Expenses [Member]
Accrued business taxes	$ 6,079	$ 5,941

Note 6 - Goodwill and Intangi_3

Note 6 - Goodwill and Intangible Assets, Net - Other Intangible Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Mar. 31, 2023
Gross carrying amount	$ 322,556	$ 328,990
Accumulated amortization	(124,876)	(112,175)
Net carrying amount	197,680	216,815
Customer Relationships [Member]
Gross carrying amount	231,543	238,247
Accumulated amortization	(94,486)	(86,058)
Net carrying amount	137,057	152,189
Intellectual Property [Member]
Gross carrying amount	66,576	65,950
Accumulated amortization	(23,160)	(19,550)
Net carrying amount	43,416	46,400
Other Intangible Assets [Member]
Gross carrying amount	24,437	24,793
Accumulated amortization	(7,230)	(6,567)
Net carrying amount	$ 17,207	$ 18,226

Note 6 - Goodwill and Intangi_4

Note 6 - Goodwill and Intangible Assets, Net - Amortization Expense for Finite-lived Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Amortization of Intangible Assets	$ 7,185	$ 7,106	$ 14,405	$ 14,426
Cost of Sales [Member]
Amortization of Intangible Assets	1,756	1,691	3,484	3,399
General and Administrative Expense [Member]
Amortization of Intangible Assets	$ 5,429	$ 5,415	$ 10,921	$ 11,027

Note 6 - Goodwill and Intangi_5

Note 6 - Goodwill and Intangible Assets, Net - Estimated Amortization Expense (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Remainder of 2024	$ 13,803
2025	26,523
2026	25,765
2027	25,270
2028	$ 24,825

Note 6 - Goodwill and Intangi_6

Note 6 - Goodwill and Intangible Assets, Net - Change in the Carrying Amount of Goodwill (Details) $ in Thousands	6 Months Ended
	Sep. 30, 2023 USD ($)
Goodwill	$ 286,444
Effect of foreign currency translation	(4,017)
Measurement period adjustment - Belyntic Acquisition	841
Goodwill	283,268
Clinical Genomics [Member] | Operating Segments [Member]
Goodwill	29,559
Effect of foreign currency translation	(201)
Measurement period adjustment - Belyntic Acquisition	0
Goodwill	29,358
Sterilization and Disinfection Control [Member] | Operating Segments [Member]
Goodwill	135,811
Effect of foreign currency translation	(180)
Measurement period adjustment - Belyntic Acquisition	0
Goodwill	135,631
Biopharmaceutical Development [Member] | Operating Segments [Member]
Goodwill	83,857
Effect of foreign currency translation	(3,612)
Measurement period adjustment - Belyntic Acquisition	841
Goodwill	81,086
Calibration Solutions [Member] | Operating Segments [Member]
Goodwill	37,217
Effect of foreign currency translation	(24)
Measurement period adjustment - Belyntic Acquisition	0
Goodwill	$ 37,193

Note 7 - Indebtedness (Details

Note 7 - Indebtedness (Details Textual) $ / shares in Units, $ in Thousands	Oct. 11, 2023 USD ($)	Mar. 05, 2021 USD ($)	Aug. 12, 2019 USD ($) $ / shares	Oct. 05, 2023 USD ($)	Sep. 30, 2023 USD ($)	Mar. 31, 2023 USD ($)
Long-Term Line of Credit					$ 0	$ 13,000
Senior Secured Credit Agreement [Member]
Long-Term Line of Credit					$ 0
Debt Instrument, Covenant, Maximum Total Leverage Ratio for the Fifth, Sixth, Seventh, and Eighth Testing Dates		4.5
Debt Instrument, Covenant, Maximum Conditional Total Leverage Ratio Following an Acquisition		5.75
Senior Secured Credit Agreement [Member] | Subsequent Event [Member]
Proceeds from Lines of Credit	$ 65,000
Long-Term Debt, Weighted Average Interest Rate, over Time	6.90%
Senior Secured Credit Agreement [Member] | Maximum [Member]
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage		0.35%
Senior Secured Credit Agreement [Member] | Maximum [Member] | The Credit Facility Term Loan [Member]
Line of Credit Facility, Maximum Borrowing Capacity		$ 75,000
Senior Secured Credit Agreement [Member] | Maximum [Member] | The Credit Facility Term Loan [Member] | Subsequent Event [Member]
Line of Credit Facility, Maximum Borrowing Capacity				$ 125,000
Senior Secured Credit Agreement [Member] | Minimum [Member]
Fixed Charge Coverage Ratio		1.25
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage		0.15%
Senior Secured Credit Agreement [Member] | Minimum [Member] | The Credit Facility Term Loan [Member]
Line of Credit Facility, Maximum Borrowing Capacity		$ 25,000
Senior Secured Credit Agreement [Member] | Swingline Loan [Member] | Maximum [Member]
Line of Credit Facility, Maximum Borrowing Capacity		5,000
The Notes [Member] | Senior Notes [Member]
Debt Instrument, Face Amount			$ 172,500
Proceeds from Convertible Debt			$ 167,056
Debt Instrument, Interest Rate, Stated Percentage			1.375%		1.375%
Debt Instrument, Convertible, Conversion Ratio Per 1,000 Principal			3.5273
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares			$ 283.5
Debt Instrument, Interest Rate, Effective Percentage					1.90%
Revolving Credit Facility [Member] | Senior Secured Credit Agreement [Member]
Line of Credit Facility, Maximum Borrowing Capacity		75,000
Letter of Credit [Member] | Senior Secured Credit Agreement [Member] | Maximum [Member]
Line of Credit Facility, Maximum Borrowing Capacity		$ 2,500

Note 7 - Indebtedness - Carryin

Note 7 - Indebtedness - Carrying Amount of the Notes (Details) - The Notes [Member] - Senior Notes [Member] - USD ($) $ in Thousands	Sep. 30, 2023	Mar. 31, 2023
Principal outstanding	$ 172,500	$ 172,500
Unamortized debt issuance costs	(1,767)	(2,228)
Net carrying value	$ 170,733	$ 170,272

Note 7 - Indebtedness - Interes

Note 7 - Indebtedness - Interest Expense on the Notes (Details) - The Notes [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Coupon interest expense at 1.375%	$ 593	$ 593	$ 1,186	$ 1,186
Amortization of debt issuance costs	231	227	461	452
Total interest and amortization of debt issuance costs	$ 824	$ 820	$ 1,647	$ 1,638

Note 8 - Stockholders' Equity_2

Note 8 - Stockholders' Equity (Details Textual) - The FY24 PSUs [Member] - Eligible Employees [Member] shares in Thousands	6 Months Ended
	Sep. 30, 2023 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) | shares	32
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share) | $ / shares	$ 132.29
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Earned, Maximum Adjustment Percentage	20%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award Number of Shares Issued Upon Vesting, Percentage	0%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award Number of Shares Issued Upon Vesting, Percentage	200%

Note 8 - Stockholders' Equity -

Note 8 - Stockholders' Equity - Allocation of Share-based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Stock-based compensation expense	$ 3,183	$ 4,371	$ 6,151	$ 7,803
Amount of income tax expense (benefit) recognized in earnings	1,389	(89)	517	(2,081)
Stock-based compensation expense, net of tax	$ 4,572	$ 4,282	$ 6,668	$ 5,722

Note 8 - Stockholders' Equity_3

Note 8 - Stockholders' Equity - Stock Option and Non-vested Stock Award Activity (Details) $ / shares in Units, shares in Thousands, $ in Thousands	6 Months Ended	12 Months Ended
	Sep. 30, 2023 USD ($) $ / shares shares	Mar. 31, 2023 USD ($) $ / shares shares
Options outstanding (in shares) | shares	163
Options outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 200.62
Outstanding, Weighted- Average Remaining Contractual Life (Year)	3 years 8 months 12 days	3 years 3 months 18 days
Outstanding, Aggregate Intrinsic Value | $	$ 0	$ 1,643
Options granted (in shares) | shares	53
Awards granted, weighted average exercise price (in dollars per share) | $ / shares	$ 131.67
Options forfeited or expired (in shares) | shares	(15)
Awards forfeited or expired, weighted average exercise price (in dollars per share) | $ / shares	$ 213.22
Awards exercised (in shares) | shares	(2)
Awards exercised, weighted average exercise price (in dollars per share) | $ / shares	$ 132.4
Options outstanding (in shares) | shares	199	163
Options outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 181.9	$ 200.62

Note 8 - Stockholders' Equity_4

Note 8 - Stockholders' Equity - Restricted Stock Unit Activity (Details)	6 Months Ended
	Sep. 30, 2023 $ / shares shares
Restricted Stock Units (RSUs) [Member]
Outstanding as of March 31, 2023(1) (in shares) | shares	57	[1]
Outstanding as of March 31, 2023(1) (in dollars per share) | $ / shares	$ 209.27	[1]
Awards granted(1) (in shares) | shares	53	[1]
Awards granted(1) (in dollars per share) | $ / shares	$ 134.35	[1]
Awards forfeited (in shares) | shares	(3)
Awards forfeited (in dollars per share) | $ / shares	$ 179.82
Awards distributed (in shares) | shares	(25)
Awards distributed, weighted average grant date fair value per share (in dollars per share) | $ / shares	$ 208.33
Outstanding as of September 30, 2023(1) (in shares) | shares	82	[1],[2]
Outstanding as of September 30, 2023(1) (in dollars per share) | $ / shares	$ 162.48	[1]
Performance Stock Units [Member]
Outstanding as of March 31, 2023(1) (in shares) | shares	44	[1]
Outstanding as of March 31, 2023(1) (in dollars per share) | $ / shares	$ 286.02	[1]
Awards granted(1) (in shares) | shares	32	[1]
Awards granted(1) (in dollars per share) | $ / shares	$ 132.29	[1]
Awards forfeited (in shares) | shares	0
Awards forfeited (in dollars per share) | $ / shares	$ 0
Awards distributed (in shares) | shares	0
Awards distributed, weighted average grant date fair value per share (in dollars per share) | $ / shares	$ 0
Outstanding as of September 30, 2023(1) (in shares) | shares	76	[1],[2]
Outstanding as of September 30, 2023(1) (in dollars per share) | $ / shares	$ 223.07	[1]
[1]Balances for PSUs are reflected at target.[2]During the nine months ended December 31, 2022, the fiscal year 2020 PSUs vested and were distributed at 126% of target, based on actual performance results and completion of service conditions.

Note 9 - Net (Loss) Earnings _3

Note 9 - Net (Loss) Earnings Per Share - Computation of Net Income Per Share, Basic & Diluted (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Net (loss)	$ (1,230)	$ 1,306	$ (1,779)	$ (132)	$ (1,779)	$ (132)
Weighted average outstanding shares of common stock (in shares)	5,387	5,323			5,379	5,298
Fully diluted shares (in shares)	5,387	5,364			5,379	5,298
Basic (loss) earnings per share (in dollars per share)	$ (0.23)	$ 0.25			$ (0.33)	$ (0.02)
Diluted (loss) earnings per share (in dollars per share)	$ (0.23)	$ 0.24			$ (0.33)	$ (0.02)
Share-Based Payment Arrangement, Option [Member]
Dilutive effect of shares (in shares)	0	27			0	0
Restricted Stock Units (RSUs) [Member]
Dilutive effect of shares (in shares)	0	14			0	0

Note 9 - Net (Loss) Earnings _4

Note 9 - Net (Loss) Earnings Per Share - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Total stock awards excluded from diluted EPS (in shares)	933	822	904	988
Assumed Conversion of Convertible Debt [Member]
Total stock awards excluded from diluted EPS (in shares)	608	608	608	608
Stock Awards that were Antidilutive [Member]
Total stock awards excluded from diluted EPS (in shares)	282	154	255	328
Stock Awards Subject to Performance Conditions [Member]
Total stock awards excluded from diluted EPS (in shares)	43	60	41	52

Note 10 - Income Taxes (Details

Note 10 - Income Taxes (Details Textual)	6 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Effective Income Tax Rate Reconciliation, Percent	21.40%	(93.50%)
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21%

Note 11 - Commitments and Con_2

Note 11 - Commitments and Contingencies (Details Textual) $ in Thousands, € in Millions	Oct. 14, 2023 EUR (€)	Sep. 30, 2023 USD ($)	Nov. 17, 2022 USD ($)
Belyntic Acquisition [Member] | Other Long-term Liabilities [Member]
Business Combination, Contingent Consideration, Liability, Noncurrent | $		$ 1,180	$ 1,500
GKE Acquisition [Member] | Subsequent Event [Member]
Business Combination, Consideration Transferred, Liabilities Incurred	€ 8.5
Business Combination, Consideration Transferred, Contingent Consideration Liability	€ 5

Note 12 - Segment Information -

Note 12 - Segment Information - Operating Segment Information (Details) - USD ($) $ in Thousands		3 Months Ended				6 Months Ended				9 Months Ended
		Sep. 30, 2023		Sep. 30, 2022		Sep. 30, 2023		Sep. 30, 2022		Sep. 30, 2023		Sep. 30, 2022
Revenues		$ 53,165		$ 58,749		$ 103,810		$ 109,202		$ 103,810		$ 109,202
Gross profit (loss)		32,109		36,386						63,292		67,727
Operating expense		32,169		32,391						64,016		68,326
Operating (loss) income		(60)		3,995						(724)		(599)
Nonoperating expense, net		(1,265)		(611)						(1,538)		(1,429)
Operating Segments [Member]
Gross profit (loss)		32,119		36,404						63,302		67,762
Operating expense		32,169		32,391						64,016		68,326
Operating (loss) income		(60)		3,995						(724)		(599)
Nonoperating expense, net		1,265		611						1,538		1,429
(Loss) earnings before income taxes		(1,325)		3,384						(2,262)		(2,028)
Operating Segments [Member] | Sterilization and Disinfection Control [Member]
Revenues		17,080	[1]	16,964	[1]	33,007		31,738		33,007	[1]	31,738	[1]
Gross profit (loss)		12,476		12,199						24,067		22,967
Operating Segments [Member] | Clinical Genomics [Member]
Revenues		15,549	[1]	18,435	[1]	28,918		32,940		28,918	[1]	32,940	[1]
Gross profit (loss)		7,727		10,641						14,455		18,490
Operating Segments [Member] | Biopharmaceutical Development [Member]
Revenues		9,207	[1]	12,144	[1]	19,096		23,111		19,096	[1]	23,111	[1]
Gross profit (loss)		5,509		7,557						11,942		14,634
Operating Segments [Member] | Calibration Solutions [Member]
Revenues		11,329	[1],[2]	11,206	[1],[2]	$ 22,789	[2]	$ 21,413	[2]	22,789	[1]	21,413	[1]
Gross profit (loss)		6,407		6,007						12,838		11,671
Corporate, Non-Segment [Member]
Revenues	[1],[3]	$ (10)		$ (18)						$ (10)		$ (35)
[1]Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.[2]Revenues in the Clinical Genomics division represent transactions subsequent to the Agena Acquisition on October 20, 2021.[3]Unallocated corporate expenses and other business activities are reported within Corporate and Other.

Note 12 - Segment Information_2

Note 12 - Segment Information - Segment Inventory (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Mar. 31, 2023
Total inventories	$ 32,879	$ 34,642
Operating Segments [Member] | Sterilization and Disinfection Control [Member]
Total inventories	3,889	3,492
Operating Segments [Member] | Clinical Genomics [Member]
Total inventories	11,330	13,985
Operating Segments [Member] | Biopharmaceutical Development [Member]
Total inventories	8,541	8,384
Operating Segments [Member] | Calibration Solutions [Member]
Total inventories	$ 9,119	$ 8,781